Fig. 2.
Pharmacological agents used in preclinical and clinical investigational therapies for neurodegeneration and their known or proposed targets related to autophagy and lysosomes. Agents whose action relates to suppression of mTORC1 activity (1), reduction of cytosolic calcium and IP3 levels as well as enhancement of TFEB activity (2-4) are expected to generally induce cellular autophagy. Targeting lysosomal acidity or glucocerebrosidase activity (5) can specifically induce lysosomal clearance efficiency